Experimental Study
Inhibitory effects of KM91104 on osteoclast differentiation and bone absorption by inhibiting nuclear factor-κB signaling pathway
Nan Wang, Fengyang Xu, Luyao Wang, Guohui Yang, Yu Meng, Jia Ren, Shengli Ma, Zongchao Xu, Juwu Chen
Published 2017-10-08
Cite as Chin J Exp Surg, 2017, 34(10): 1725-1727. DOI: 10.3760/cma.j.issn.1001-9030.2017.10.033
Abstract
ObjectiveTo investigate the effect of KM91104 on osteoclast differentiation and bone absorption and the mechanism.
MethodsBone marrow mononuclear macrophage in vitro was cultured, effects of KM91104 (0-40 μmol/L) on osteoclast progenitor cell proliferation, differentiation of osteoclasts, osteoclast bone absorption and osteoclast specific gene expression were observed, and the molecular mechanism of osteoclast function was investigated by Western bloting.
ResultsAfter treatment of 0, 1.25, 2.50, 5.00 μmol/L of KM91104, the osteoclast counts were respectively 116.67±9.713, 79.67±16.166, 62.33±21.825, 27.33±13.650 (F=16.268, P=0.001). After treatment of 1.25, 2.50, 5.00 μmol/L of KM91104, the bone absorption regions were significantly reduced with the concentration dependence. After treatment of 0, 1.25, 2.50 μmol/L of KM91104, the relative expression of nuclear factor of activated T cells c1 (NFATc1) gene were respectively 0.767±0.010, 0.509±0.012, 0.425±0.009 (F=1 773.069, P=0.000); the relative expression of tartrate resistant acid phosphatase (TRACP) gene were respectively 0.412±0.008, 0.314±0.010, 0.257±0.009 (F=466.743, P=0.000); the relative expression of cathepsin K (CtsK) gene were respectively 0.875±0.011, 0.756±0.007, 0.553±0.009 (F=1 868.721, P=0.000). After treatment of 0, 1.25, 2.50 μmol/L of KM91104, the protein grayscale of phosphorylated p65 (p-p65)/p65 were respectively 0.419±0.011, 0.213±0.036, 0.133±0.006 (F=273.988, P=0.000); the protein grayscale of phosphorylated inhibitory κB-α (p-IκB-α)/inhibitory κB-α (IκB-α) were respectively 0.846±0.021, 0.512±0.053, 0.388±0.011 (F=293.710, P=0.000).
ConclusionKM91104 inhibits the osteoclast differentiation and bone absorption, and can be used to treat osteoporosis.
Key words:
Osteoporosis; Osteoclast; KM91104; Nuclear factor-κB
Contributor Information
Nan Wang
Department of Emergency Surgery, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China
Fengyang Xu
Department of Emergency Surgery, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China
Luyao Wang
Department of Stomatology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China
Guohui Yang
Department of Emergency Surgery, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China
Yu Meng
Department of Emergency Surgery, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China
Jia Ren
Department of Emergency Surgery, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China
Shengli Ma
Department of Emergency Surgery, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China
Zongchao Xu
Department of Emergency Surgery, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China
Juwu Chen
Department of Emergency Surgery, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China
